Immunotherapies have revolutionized the treatment of Non-Small Cell Lung Cancer. These therapies work by stimulating the patient's immune system to recognize and attack cancer cells. The use of immune checkpoint inhibitors such as pembrolizumab and nivolumab has significantly improved the survival rates of NSCLC patients. These therapies are particularly effective in patients with high levels of programmed death-ligand 1 (PD-L1) expression. The use of combination therapies, such as immune checkpoint inhibitors and chemotherapy, has also shown promising results in NSCLC patients.
Liquid biopsy is a non-invasive method for diagnosing and monitoring Non-Small Cell Lung Cancer Market. It involves the analysis of tumor DNA and other biomarkers in a patient's blood. The use of liquid biopsy has significant advantages over traditional tissue biopsy, including a lower risk of complications, the ability to monitor disease progression, and the potential for early detection of resistance to treatment.
Explore More- https://cmi-latestreportorientedblogs.blogspot.com/2023/04/the-non-small-cell-lung-cancer-market.html
